5 record-breaking biotech deals

The one bright spot in M&A in 2008 are drugmakers, where giant pharmaceutical companies are paying record amounts for biotechs to replenish their pipelines.

1 of 5
Value: $42.6 billion

Announced: July 2008

Switzerland's Roche bought a controlling stake in the early 1990s in Genentech, which was then still trying to get its first drugs to market. But it allowed it operate independently, and the results have been spectacular: The oncology-focused lab has produced three of biotech's 10 best-selling drugs: Rituxan for Non-Hodgkin's lymphoma, Herceptin for breast cancer, and Avastin, a potential blockbuster which is still in testing for use on up to 30 different cancers.

Now Roche wants all of Genentech, though the South San Francisco-based company rejected the offer as too low. When Fortune named Genentech the No. 1 place to work in America in 2006, workers said they loved not being part of Big Pharma. Will a product-hungry giant like Roche change the way things run at Genentech, and quash its culture of innovation? Will they cancel the keggers?
NEXT: AstraZeneca/MedImmune
Last updated September 08 2008: 10:23 AM ET
Source: Dealogic
The best healthcare fix McCain's plan is the only one that has a chance of getting medical costs under control. An argument for some free-market sanity. (more)
The next President will have a fighting chance to defeat the lobbyists and reform a broken system. (more)

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © 2018 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc. 2018. All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2018 and/or its affiliates.